Edgewise Therapeutics, Inc. Logo

Edgewise Therapeutics, Inc.

Developing novel therapeutics for rare and serious muscle disorders.

EWTX | NDAQ

Overview

Corporate Details

ISIN(s):
US28036F1057
LEI:
Country:
United States of America
Address:
1715 38TH ST, 80301 BOULDER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare and serious muscle disorders. Founded in 2017, the company leverages its specialized expertise and singular focus on muscle science to create precision medicines for debilitating skeletal and cardiac muscle diseases, such as muscular dystrophies. Edgewise is committed to addressing significant unmet medical needs for patients with these conditions through its innovative scientific approach.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Edgewise Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Edgewise Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Edgewise Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea 402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom CNSL
Camp4 Therapeutics Corp Logo
Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.
United States of America CAMP
Camurus Logo
Develops long-acting medicines for severe chronic diseases using advanced drug delivery.
Sweden CAMX
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan 4575
Candel Therapeutics, Inc. Logo
Developing off-the-shelf viral immunotherapies to help the immune system fight solid tumors.
United States of America CADL
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel CANF
Can-Fite BioPharma Ltd. Logo
Clinical-stage biopharma developing oral drugs for cancer, inflammatory, liver & metabolic diseases.
United States of America CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany 27N0

Talk to a Data Expert

Have a question? We'll get back to you promptly.